A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection

Highlights•Our goal is to produce antibodies to immune evasion domains through immunization. •Antibodies produced by HSV infection bind gC2 yet do not block gC2 binding to C3b. •Antibodies produced by immunization bind gC2 and prevent C3b from binding. •Immunizing infected animals produces gC2 antib...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2019-01, Vol.37 (4), p.664-669
Main Authors: Hook, Lauren M, Awasthi, Sita, Dubin, Jonathan, Flechtner, Jessica, Long, Deborah, Friedman, Harvey M
Format: Article
Language:English
Subjects:
Adjuvants
Adjuvants, Immunologic - administration & dosage
Allergy and Immunology
Aluminum sulfate
Animals
Antibodies
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
Antigens
Blocking
Cell surface
Complement C3b
Complement C3b - immunology
CpG islands
Domains
Female
Genital herpes
Glycoprotein C
Glycoprotein D
Glycoproteins
Guinea Pigs
Herpes Genitalis - prevention & control
Herpes simplex
Herpes simplex virus
Herpes viruses
Herpesvirus 2, Human
Human subjects
Humans
Hypotheses
Immune Evasion
Immunization
Immunoglobulins
Infections
Inoculation
Laboratory animals
Proteins
Public health
Vaccine
Vaccine development
Vaccines
Viral Envelope Proteins - genetics
Viral Envelope Proteins - immunology
Viral Vaccines - administration & dosage
Viral Vaccines - immunology
Virions
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c550t-256a28503aa6b0f36921ead848035799264da6f1346bc808851d4991f825c6eb3
cites cdi_FETCH-LOGICAL-c550t-256a28503aa6b0f36921ead848035799264da6f1346bc808851d4991f825c6eb3
container_end_page 669
container_issue 4
container_start_page 664
container_title Vaccine
container_volume 37
creator Hook, Lauren M
Awasthi, Sita
Dubin, Jonathan
Flechtner, Jessica
Long, Deborah
Friedman, Harvey M
description Highlights•Our goal is to produce antibodies to immune evasion domains through immunization. •Antibodies produced by HSV infection bind gC2 yet do not block gC2 binding to C3b. •Antibodies produced by immunization bind gC2 and prevent C3b from binding. •Immunizing infected animals produces gC2 antibodies that prevent C3b from binding. •Vaccines make the weakly immunogenic immune evasion domains of gC2 more immunogenic.
doi_str_mv 10.1016/j.vaccine.2018.11.076
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6447314</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X18316396</els_id><sourcerecordid>2165629766</sourcerecordid><originalsourceid>FETCH-LOGICAL-c550t-256a28503aa6b0f36921ead848035799264da6f1346bc808851d4991f825c6eb3</originalsourceid><addsrcrecordid>eNqFks-O0zAQxiMEYsvCI4AsceHSrieOXeeyaFWWP9JKHACJm-U4k9bdxC62E9F34WFx1VLBXjhYtuzffOOZb4riJdAFUBBX28WkjbEOFyUFuQBY0KV4VMxALtm85CAfFzNaimpeAf1-UTyLcUsp5Qzqp8UFo5xDLcWs-HVDUrCT7tElsl6VV-t3ed2W5KROOh_IBsMOI4l22PX4k0w2jJGs0WHQKd9rl2zj2z0JGHfexXyVNjqRpvfmnthhGLMOTjpa70jrB21dJPmY05EGU8Jw4B1xOo1B98S6Dk3K8PPiSaf7iC9O-2Xx7f3t19XH-d3nD59WN3dzwzlNuVqhS8kp01o0tGOiLgF1KytJGV_Wde5Cq0UHrBKNkVRKDm1V19DJkhuBDbssro-6u7EZsDW5F_kfahfsoMNeeW3Vvy_ObtTaT0pU1ZJBlQXenASC_zFiTGqw0WDfa4d-jKoEvhRC8CXP6OsH6NaPweXyMiW4KOtMZoofKRN8jAG782eAqoP_aqtODqmD_wpAZf9z3Ku_KzlH_TE8A2-PAOZ-ThaDisaiM9jakJuuWm__m-L6gYLprbNG9_e4x3iuBlQsFVVfDkN4mEGQDASrBfsNUMja6Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2165629766</pqid></control><display><type>article</type><title>A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection</title><source>ScienceDirect Journals</source><creator>Hook, Lauren M ; Awasthi, Sita ; Dubin, Jonathan ; Flechtner, Jessica ; Long, Deborah ; Friedman, Harvey M</creator><creatorcontrib>Hook, Lauren M ; Awasthi, Sita ; Dubin, Jonathan ; Flechtner, Jessica ; Long, Deborah ; Friedman, Harvey M</creatorcontrib><description>Highlights•Our goal is to produce antibodies to immune evasion domains through immunization. •Antibodies produced by HSV infection bind gC2 yet do not block gC2 binding to C3b. •Antibodies produced by immunization bind gC2 and prevent C3b from binding. •Immunizing infected animals produces gC2 antibodies that prevent C3b from binding. •Vaccines make the weakly immunogenic immune evasion domains of gC2 more immunogenic.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2018.11.076</identifier><identifier>PMID: 30551986</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adjuvants ; Adjuvants, Immunologic - administration &amp; dosage ; Allergy and Immunology ; Aluminum sulfate ; Animals ; Antibodies ; Antibodies, Neutralizing - blood ; Antibodies, Viral - blood ; Antigens ; Blocking ; Cell surface ; Complement C3b ; Complement C3b - immunology ; CpG islands ; Domains ; Female ; Genital herpes ; Glycoprotein C ; Glycoprotein D ; Glycoproteins ; Guinea Pigs ; Herpes Genitalis - prevention &amp; control ; Herpes simplex ; Herpes simplex virus ; Herpes viruses ; Herpesvirus 2, Human ; Human subjects ; Humans ; Hypotheses ; Immune Evasion ; Immunization ; Immunoglobulins ; Infections ; Inoculation ; Laboratory animals ; Proteins ; Public health ; Vaccine ; Vaccine development ; Vaccines ; Viral Envelope Proteins - genetics ; Viral Envelope Proteins - immunology ; Viral Vaccines - administration &amp; dosage ; Viral Vaccines - immunology ; Virions ; Viruses</subject><ispartof>Vaccine, 2019-01, Vol.37 (4), p.664-669</ispartof><rights>Elsevier Ltd</rights><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><rights>2018. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c550t-256a28503aa6b0f36921ead848035799264da6f1346bc808851d4991f825c6eb3</citedby><cites>FETCH-LOGICAL-c550t-256a28503aa6b0f36921ead848035799264da6f1346bc808851d4991f825c6eb3</cites><orcidid>0000-0002-5540-2459 ; 0000-0002-7034-7689</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30551986$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hook, Lauren M</creatorcontrib><creatorcontrib>Awasthi, Sita</creatorcontrib><creatorcontrib>Dubin, Jonathan</creatorcontrib><creatorcontrib>Flechtner, Jessica</creatorcontrib><creatorcontrib>Long, Deborah</creatorcontrib><creatorcontrib>Friedman, Harvey M</creatorcontrib><title>A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Highlights•Our goal is to produce antibodies to immune evasion domains through immunization. •Antibodies produced by HSV infection bind gC2 yet do not block gC2 binding to C3b. •Antibodies produced by immunization bind gC2 and prevent C3b from binding. •Immunizing infected animals produces gC2 antibodies that prevent C3b from binding. •Vaccines make the weakly immunogenic immune evasion domains of gC2 more immunogenic.</description><subject>Adjuvants</subject><subject>Adjuvants, Immunologic - administration &amp; dosage</subject><subject>Allergy and Immunology</subject><subject>Aluminum sulfate</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Neutralizing - blood</subject><subject>Antibodies, Viral - blood</subject><subject>Antigens</subject><subject>Blocking</subject><subject>Cell surface</subject><subject>Complement C3b</subject><subject>Complement C3b - immunology</subject><subject>CpG islands</subject><subject>Domains</subject><subject>Female</subject><subject>Genital herpes</subject><subject>Glycoprotein C</subject><subject>Glycoprotein D</subject><subject>Glycoproteins</subject><subject>Guinea Pigs</subject><subject>Herpes Genitalis - prevention &amp; control</subject><subject>Herpes simplex</subject><subject>Herpes simplex virus</subject><subject>Herpes viruses</subject><subject>Herpesvirus 2, Human</subject><subject>Human subjects</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Immune Evasion</subject><subject>Immunization</subject><subject>Immunoglobulins</subject><subject>Infections</subject><subject>Inoculation</subject><subject>Laboratory animals</subject><subject>Proteins</subject><subject>Public health</subject><subject>Vaccine</subject><subject>Vaccine development</subject><subject>Vaccines</subject><subject>Viral Envelope Proteins - genetics</subject><subject>Viral Envelope Proteins - immunology</subject><subject>Viral Vaccines - administration &amp; dosage</subject><subject>Viral Vaccines - immunology</subject><subject>Virions</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqFks-O0zAQxiMEYsvCI4AsceHSrieOXeeyaFWWP9JKHACJm-U4k9bdxC62E9F34WFx1VLBXjhYtuzffOOZb4riJdAFUBBX28WkjbEOFyUFuQBY0KV4VMxALtm85CAfFzNaimpeAf1-UTyLcUsp5Qzqp8UFo5xDLcWs-HVDUrCT7tElsl6VV-t3ed2W5KROOh_IBsMOI4l22PX4k0w2jJGs0WHQKd9rl2zj2z0JGHfexXyVNjqRpvfmnthhGLMOTjpa70jrB21dJPmY05EGU8Jw4B1xOo1B98S6Dk3K8PPiSaf7iC9O-2Xx7f3t19XH-d3nD59WN3dzwzlNuVqhS8kp01o0tGOiLgF1KytJGV_Wde5Cq0UHrBKNkVRKDm1V19DJkhuBDbssro-6u7EZsDW5F_kfahfsoMNeeW3Vvy_ObtTaT0pU1ZJBlQXenASC_zFiTGqw0WDfa4d-jKoEvhRC8CXP6OsH6NaPweXyMiW4KOtMZoofKRN8jAG782eAqoP_aqtODqmD_wpAZf9z3Ku_KzlH_TE8A2-PAOZ-ThaDisaiM9jakJuuWm__m-L6gYLprbNG9_e4x3iuBlQsFVVfDkN4mEGQDASrBfsNUMja6Q</recordid><startdate>20190121</startdate><enddate>20190121</enddate><creator>Hook, Lauren M</creator><creator>Awasthi, Sita</creator><creator>Dubin, Jonathan</creator><creator>Flechtner, Jessica</creator><creator>Long, Deborah</creator><creator>Friedman, Harvey M</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5540-2459</orcidid><orcidid>https://orcid.org/0000-0002-7034-7689</orcidid></search><sort><creationdate>20190121</creationdate><title>A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection</title><author>Hook, Lauren M ; Awasthi, Sita ; Dubin, Jonathan ; Flechtner, Jessica ; Long, Deborah ; Friedman, Harvey M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c550t-256a28503aa6b0f36921ead848035799264da6f1346bc808851d4991f825c6eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adjuvants</topic><topic>Adjuvants, Immunologic - administration &amp; dosage</topic><topic>Allergy and Immunology</topic><topic>Aluminum sulfate</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Neutralizing - blood</topic><topic>Antibodies, Viral - blood</topic><topic>Antigens</topic><topic>Blocking</topic><topic>Cell surface</topic><topic>Complement C3b</topic><topic>Complement C3b - immunology</topic><topic>CpG islands</topic><topic>Domains</topic><topic>Female</topic><topic>Genital herpes</topic><topic>Glycoprotein C</topic><topic>Glycoprotein D</topic><topic>Glycoproteins</topic><topic>Guinea Pigs</topic><topic>Herpes Genitalis - prevention &amp; control</topic><topic>Herpes simplex</topic><topic>Herpes simplex virus</topic><topic>Herpes viruses</topic><topic>Herpesvirus 2, Human</topic><topic>Human subjects</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Immune Evasion</topic><topic>Immunization</topic><topic>Immunoglobulins</topic><topic>Infections</topic><topic>Inoculation</topic><topic>Laboratory animals</topic><topic>Proteins</topic><topic>Public health</topic><topic>Vaccine</topic><topic>Vaccine development</topic><topic>Vaccines</topic><topic>Viral Envelope Proteins - genetics</topic><topic>Viral Envelope Proteins - immunology</topic><topic>Viral Vaccines - administration &amp; dosage</topic><topic>Viral Vaccines - immunology</topic><topic>Virions</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hook, Lauren M</creatorcontrib><creatorcontrib>Awasthi, Sita</creatorcontrib><creatorcontrib>Dubin, Jonathan</creatorcontrib><creatorcontrib>Flechtner, Jessica</creatorcontrib><creatorcontrib>Long, Deborah</creatorcontrib><creatorcontrib>Friedman, Harvey M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hook, Lauren M</au><au>Awasthi, Sita</au><au>Dubin, Jonathan</au><au>Flechtner, Jessica</au><au>Long, Deborah</au><au>Friedman, Harvey M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2019-01-21</date><risdate>2019</risdate><volume>37</volume><issue>4</issue><spage>664</spage><epage>669</epage><pages>664-669</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Highlights•Our goal is to produce antibodies to immune evasion domains through immunization. •Antibodies produced by HSV infection bind gC2 yet do not block gC2 binding to C3b. •Antibodies produced by immunization bind gC2 and prevent C3b from binding. •Immunizing infected animals produces gC2 antibodies that prevent C3b from binding. •Vaccines make the weakly immunogenic immune evasion domains of gC2 more immunogenic.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>30551986</pmid><doi>10.1016/j.vaccine.2018.11.076</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-5540-2459</orcidid><orcidid>https://orcid.org/0000-0002-7034-7689</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2019-01, Vol.37 (4), p.664-669
issn 0264-410X
1873-2518
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6447314
source ScienceDirect Journals
subjects Adjuvants
Adjuvants, Immunologic - administration & dosage
Allergy and Immunology
Aluminum sulfate
Animals
Antibodies
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
Antigens
Blocking
Cell surface
Complement C3b
Complement C3b - immunology
CpG islands
Domains
Female
Genital herpes
Glycoprotein C
Glycoprotein D
Glycoproteins
Guinea Pigs
Herpes Genitalis - prevention & control
Herpes simplex
Herpes simplex virus
Herpes viruses
Herpesvirus 2, Human
Human subjects
Humans
Hypotheses
Immune Evasion
Immunization
Immunoglobulins
Infections
Inoculation
Laboratory animals
Proteins
Public health
Vaccine
Vaccine development
Vaccines
Viral Envelope Proteins - genetics
Viral Envelope Proteins - immunology
Viral Vaccines - administration & dosage
Viral Vaccines - immunology
Virions
Viruses
title A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T01%3A13%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20trivalent%20gC2/gD2/gE2%20vaccine%20for%20herpes%20simplex%20virus%20generates%20antibody%20responses%20that%20block%20immune%20evasion%20domains%20on%20gC2%20better%20than%20natural%20infection&rft.jtitle=Vaccine&rft.au=Hook,%20Lauren%20M&rft.date=2019-01-21&rft.volume=37&rft.issue=4&rft.spage=664&rft.epage=669&rft.pages=664-669&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2018.11.076&rft_dat=%3Cproquest_pubme%3E2165629766%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c550t-256a28503aa6b0f36921ead848035799264da6f1346bc808851d4991f825c6eb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2165629766&rft_id=info:pmid/30551986&rfr_iscdi=true